I'm expecting from Cohort 3 a beneficial effect to the patients HCV. In other words a knock down of the virus. In other words TT-034 works.
The company is expecting the same as the results from Cohort 4 will be 2016.
- Forums
- ASX - By Stock
- BLT
- Updated listing price
Updated listing price, page-36
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)